Aslı YILDIRIM, Gulsum KAYA, Hasan ERGENC
Annals of Clinical and Analytical Medicine - 2026;17(4):324-328
Aim: The goal of this study was to find out easily applicable laboratory parameters to predict the response and outcome of patients receiving immunotherapy treatments in routine oncology clinics. Methods: Patients who were followed up in the oncology outpatient clinic, diagnosed with CA, and received immunotherapy were included in this study. Demographic, diagnostic, laboratory, pathology, treatment, and duration of ımmunotherapy response data were extracted from the medical history of patients, radiological assessments, and pathology reports in both patient files and electronic records. The obtained data were analyzed in the SPSS program, and the significance level was taken as p<0.05. Results: This study recruited 80 patients, 21 females and 59 males, diagnosed with advanced-stage solid tumors treated with immunotherapy with or without chemotherapy. Statistically significant longer median response duration in patients with serum CRP level <10 mg/L was detected when compared to patients with higher CRP >=10 mg/L (372 and 227 days, respectively, p<0.001). Moreover, there was a statistically significant difference between serum albumin and monocyte levels of patients with CRP level <10 mg/L and patients with CRP >=10 mg/L in terms of immunotherapy response duration (p<0.001 and 0.017, respectively). Peripheral blood albumin < 4mg/dl and monocyte >0.6x103L were related to decreased duration of response to immunotherapies. Conclusion: Routine peripheral blood C-reactive protein, albumin, and monocyte levels may predict who will get more benefit from novel immunotherapeutic agents.
